Wetland Manipulation in the Yalahau Region of the Northern Maya Lowlands

Manipulation of wetlands for agricultural purposes by the ancient Maya of southern Mexico and Central America has been a subject of much research and debate since the 1970s. Evidence for wetland cultivation systems, in the form of drained or channelized fields, and raised planting platforms, has been restricted primarily to the southern Maya Lowlands. New research in the Yalahau region of Quintana Roo, Mexico, has recorded evidence for wetland manipulation in the far northern lowlands, in the form of rock alignments that apparently functioned to control water movement and soil accumulation in seasonally inundated areas. Nearby ancient settlements date primarily to the Late Preclassic period (ca. 100 B.C. to A.C. 350), and this age is tentatively attributed to wetland management in the area

A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk

Colorectal cancer risk can be impacted by genetic, environmental, and lifestyle factors, including diet and obesity. Geneenvironment interactions (G x E) can provide biological insights into the effects of obesity on colorectal cancer risk. Here, we assessed potential genome-wide G x E interactions between body mass index (BMI) and common SNPs for colorectal cancer risk using data from 36,415 colorectal cancer cases and 48,451 controls from three international colorectal cancer consortia (CCFR, CORECT, and GECCO). The G x E tests included the conventional logistic regression using multiplicative terms (one degree of freedom, 1DF test), the two-step EDGE method, and the joint 3DF test, each of which is powerful for detecting G x E interactions under specific conditions. BMI was associated with higher colorectal cancer risk. The two-step approach revealed a statistically significant GxBMI interaction located within the Formin 1/Gremlin 1 (FMN1/GREM1) gene region (rs58349661). This SNP was also identified by the 3DF test, with a suggestive statistical significance in the 1DF test. Among participants with the CC genotype of rs58349661, overweight and obesity categories were associated with higher colorectal cancer risk, whereas null associations were observed across BMI categories in those with the TT genotype. Using data from three large international consortia, this study discovered a locus in the FMN1/GREM1 gene region that interacts with BMI on the association with colorectal cancer risk. Further studies should examine the potential mechanisms through which this locus modifies the etiologic link between obesity and colorectal cancer

Robust estimation of bacterial cell count from optical density

Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Lifeways in the Northern Mayan Lowlands: New Approaches to Archaeology in the Yucatán Peninsula

The flat, dry reaches of the northern Yucatán Peninsula have been largely ignored by archaeologists drawn to the more illustrious sites of the south. This book is the first volume to focus entirely on the northern Maya lowlands, presenting a broad cross-section of current research projects in the region by both established and up-and-coming scholars. To address the heretofore unrecognized importance of the northern lowlands in Maya prehistory, the contributors cover key topics relevant to Maya studies: the environmental and historical significance of the region, the archaeology of both large and small sites, the development of agriculture, resource management, ancient politics, and long-distance interaction among sites. As a volume in the series Native Peoples of the Americas, it adds a human dimension to archaeological findings by incorporating modern ethnographic data.By exploring various social and political levels of Maya society through a broad expanse of time, Lifeways in the Northern Maya Lowlands not only reconstructs a little-known past, it also suggests the broad implications of archaeology for related studies of tourism, household economies, and ethnoarchaeology. It is a benchmark work that pointedly demonstrates the need for researchers in both north and south to ignore modern geographic boundaries in their search for new ideas to further their understanding of the ancient Maya.https://digitalcommons.trinity.edu/mono/1140/thumbnail.jp

Characteristics of diazotrophs in surface to abyssopelagic waters of the Sargasso Sea

The presence and expression of nitrogenase genes in diazotrophic prokaryotes has been documented in oligotrophic surface waters of the North Pacific gyre; however, there have been few investigations in other ocean basins. We initiated a study into the ecology of planktonic diazotrophs at 4 stations in the Sargasso Sea. Nucleic acid samples from the surface to 5890 m were collected on several dates between October 2003 and September 2005. Surprisingly, nifH could only be amplified from nano- and picoplankton DNA in surface waters on only 1 of 2 sampling dates at 1 station in the Sargasso Sea. Although no nifH was detected in the surface DNA samples earlier in the year at that station, Crocosphaera sp. cyanobacterial nifH was detected in enrichment cultures initiated with surface water collected at the time. In contrast to surface waters, diazotrophs were more consistently detected in deeper waters, including at several stations elsewhere globally. The nifH microarray fingerprints from the Sargasso Sea from 0, 5 and 25 m depths were remarkably consistent between samples taken 2 yr apart, but were different from fingerprints from subeuphotic waters. The results of our study suggest the presence of diazotrophic plankton in the Sargasso Sea, which is not constrained to surface waters. Furthermore, our study demonstrates that a deep-water diazotrophic flora persists in the meso- and abyssopelagic zones in the presence of high concentrations of combined nitrogen; however, the gene expression patterns of such species and their role in the N cycle remain unknown. © Inter-Research 2007

Neither full length VAR2CSA nor designs show strain transcending activity.

(A) The BIA assay results against WF12 parasite strain containing 7G8 VAR2CSA using purified pooled IgG at 1mg/ml from the serum after three vaccinations. (B) The BIA assay results against CS2 parasite strain containing FCR3 VAR2CSA using purified pooled IgG at 4mg/ml from the serum after three vaccinations. The dashed line indicates the 50% inhibition level used as a cutoff for inhibitory or non-inhibitory activity, the data shown are derived from two independent experiments and each point is the mean of two technical replicates. (TIFF)</p